Compare Gap Inc (GAP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Sana Biotechnology Inc — how do they compare? Gap Inc trades at $20.21 (market cap $7.55B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: Gap Inc is far larger — about 6.7× Sana Biotechnology Inc's market cap, and Gap Inc pays a 3.34% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| GAP | SANA | |
|---|---|---|
Market Cap | $7.55B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $5.92 |
52-Week Low | $18.35 | $2.68 |
Enterprise Value | $10.63B | $1.05B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $20.17, down 6.23% over the past day, with a bullish technical outlook supported by moving averages and strong momentum indicators. Fundamentally, the company shows robust profitability with a 40.5% gross margin and 27.58% ROE, while valuation ratios like P/E of 8.32 and P/S of 0.52 suggest undervaluation. Recent earnings have mostly beaten expectations, and cash flow trends are positive, with Q2 2026 results due August 27.
The stock presents a compelling value opportunity with upside to the $26.09 consensus price target, though risks include competitive pressures and ongoing investigations. Investor sentiment is mixed amid turnaround efforts, with analysts largely neutral but highlighting digital transformation and denim strength as growth catalysts.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
